The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
The assay is based on the company's AmpiProbe technology, which uses fluorescent reporter-labeled primers and quencher-labeled primers to amplify DNA.
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
The company's clinical services revenues were down 34 percent year over year while product revenues ticked up 7 percent.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.
The improvement in the 360Dx Index was modest compared to 2017, but it still outpaced the broader markets, which fell dramatically in the last month of the year.
The firm said clinical services revenues fell during the quarter due to reduced insurance reimbursement payments and mix of testing in the prior year.